Hemp
Hemp CBDA and CBGA block cellular entry of SARS-CoV-2 and other variants
CBDA (cannabidiolic acid) and CBGA (cannabigerolic acid), two cannabinoids present in industrial hemp flowers, block the cellular entry of SARS-CoV-2 and the emerging variants, reveals a study da Oregon State University, in the United States of America (USA), led by the researcher Richard van Breemen. The results of this pre-clinical investigation (only done in the laboratory and not with humans) were published this week in PubMed and ACS – Chemistry for Life and confirm that the two cannabinoids in acidic form (found in the raw flowers of the plant) bind to the Spike protein, preventing the Covid virus from penetrating the cells.
The news is reaching the media mainstream, as Forbes or the Public, and reports the benefits of cannabinoids in the disease caused by SARS-CoV-2, already advanced in a investigation carried out by Cannareporter precisely one year ago, in January 2021.
The research team led by van Breemen, PhD professor and principal investigator at the Faculty of Pharmacy and the Global Hemp Innovation Center from the University, discovered that CBDA and CBGA, two components of hemp, one of the Cannabis sativa low in THC (tetrahydrocannabinol)), can bind to the “peaks” present in the protein spike of SARS-CoV-2, preventing the virus from penetrating cells.
According to Richard van Breemen, “These acidic cannabinoids are abundant in hemp and many hemp extracts”, explained the professor in the University communiqué, who released your extensive work. Van Breemen further pointed out that these cannabinoids "can be ingested orally" and "have a good safety profile" in humans. “This means that substances that inhibit the entry of the virus into cells, such as hemp acids, could be used to prevent a SARS-CoV-2 infection”, explains the researcher.
Hemp is also effective in other variants such as Alpha and Beta
In addition to these results, hemp components also proved to be effective against other variants of the coronavirus. “Our investigation showed that hemp components were equally effective against variants of SARS-CoV-2, including variant B.1.1.7, which was first detected in the UK, and variant B.1.351, which was detected for the first time in South Africa”, said Van Breemen, citing the two variants, Alpha and Beta, respectively.
Cannareporter has sent questions to researcher Richard van Breemen and will publish an interview with the researcher once it has the answers.
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!
With a degree in Journalism from the University of Coimbra, Laura Ramos has a postgraduate degree in Photography and has been a Journalist since 1998. Winner of the Business of Cannabis Awards in the category "Journalist of the Year 2024", Laura was a correspondent for Jornal de Notícias in Rome, Italy, and Press Officer in the Office of the Minister of Education of the 21st Portuguese Government. She has an international certification in Permaculture (PDC) and created the street-art photography archive “Say What? Lisbon” @saywhatlisbon. Co-founder and Editor of CannaReporter® and coordinator of PTMC - Portugal Medical Cannabis, Laura directed the documentary “Pacientes” and was part of the steering group of the first Postgraduate Course in GxP's for Medicinal Cannabis in Portugal, in partnership with the Military Laboratory and the Faculty of Pharmacy of the University of Lisbon.



